791 related articles for article (PubMed ID: 9012539)
1. Antitumor effects of human recombinant interleukin-1 alpha and etoposide against human tumor cells: mechanism for synergism in vitro and activity in vivo.
Usui N; Matsushima K; Pilaro AM; Longo DL; Wiltrout RH
Biotherapy; 1996; 9(4):199-208. PubMed ID: 9012539
[TBL] [Abstract][Full Text] [Related]
2. A role for the interleukin 1 receptor in the synergistic antitumor effects of human interleukin 1 alpha and etoposide against human melanoma cells.
Usui N; Mimnaugh EG; Sinha BK
Cancer Res; 1991 Feb; 51(3):769-74. PubMed ID: 1824825
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor activity of etoposide and human interleukin-1 alpha against human melanoma cells.
Usui N; Mimnaugh EG; Sinha BK
J Natl Cancer Inst; 1989 Dec; 81(24):1904-9. PubMed ID: 2593167
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antiproliferative effects of the combination of interleukin-1 alpha and doxorubicin against human melanoma cells.
Mimnaugh EG; Monti E; Sebers S; Stetler-Stevenson M; Sinha BK
Oncol Res; 1992; 4(10):401-12. PubMed ID: 1292755
[TBL] [Abstract][Full Text] [Related]
5. Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.
Futami H; Jansen R; MacPhee MJ; Keller J; McCormick K; Longo DL; Oppenheim JJ; Ruscetti FW; Wiltrout RH
J Immunol; 1990 Dec; 145(12):4121-30. PubMed ID: 2258610
[TBL] [Abstract][Full Text] [Related]
6. Synergistic interactions of etoposide and interleukin-1 alpha are not due to DNA damage in human melanoma cells.
Monti E; Mimnaugh EG; Sinha BK
Biochim Biophys Acta; 1993 Jan; 1180(3):231-5. PubMed ID: 8422427
[TBL] [Abstract][Full Text] [Related]
7. Autocrine interleukin-1 receptor antagonist can support malignant growth of glioblastoma by blocking growth-inhibiting autocrine loop of interleukin-1.
Oelmann E; Kraemer A; Serve H; Reufi B; Oberberg D; Patt S; Herbst H; Stein H; Thiel E; Berdel WE
Int J Cancer; 1997 Jun; 71(6):1066-76. PubMed ID: 9185713
[TBL] [Abstract][Full Text] [Related]
8. Sensitization by interleukin-1alpha of carboplatinum anti-tumor activity against human ovarian (NIH:OVCAR-3) carcinoma cells in vitro and in vivo.
Wang Z; Lee KB; Reed E; Sinha BK
Int J Cancer; 1996 Nov; 68(5):583-7. PubMed ID: 8938138
[TBL] [Abstract][Full Text] [Related]
9. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.
McIntosh JK; Mulé JJ; Krosnick JA; Rosenberg SA
Cancer Res; 1989 Mar; 49(6):1408-14. PubMed ID: 2784349
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha.
McIntosh JK; Mulé JJ; Merino MJ; Rosenberg SA
Cancer Res; 1988 Jul; 48(14):4011-7. PubMed ID: 3260130
[TBL] [Abstract][Full Text] [Related]
11. [Experimental studies on treatment of nasopharyngeal carcinoma with combination regimen of hydroxycamptothecin and etoposide].
Liang YJ; Fu LW; Ding Y; Xiong HY; Chen LM; Yang XP; Pan QC
Ai Zheng; 2003 Apr; 22(4):368-71. PubMed ID: 12703990
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 trial of recombinant human interleukin-1 beta (rhIL-1 beta), carboplatin, and etoposide in patients with solid cancers: Southwest Oncology, Group Study 8940.
Rinehart J; Hersh E; Issell B; Triozzi P; Buhles W; Neidhart J
Cancer Invest; 1997; 15(5):403-10. PubMed ID: 9316621
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human interleukin-4 inhibits growth of some human lung tumor cell lines in vitro and in vivo.
Topp MS; Koenigsmann M; Mire-Sluis A; Oberberg D; Eitelbach F; von Marschall Z; Notter M; Reufi B; Stein H; Thiel E
Blood; 1993 Nov; 82(9):2837-44. PubMed ID: 8219232
[TBL] [Abstract][Full Text] [Related]
14. Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
Iguchi M; Matsumoto M; Hojo K; Wada T; Matsuo Y; Arimura A; Abe K
Jpn J Clin Oncol; 2009 May; 39(5):303-9. PubMed ID: 19336449
[TBL] [Abstract][Full Text] [Related]
15. Embryonic implantation in mice is blocked by interleukin-1 receptor antagonist.
Simón C; Frances A; Piquette GN; el Danasouri I; Zurawski G; Dang W; Polan ML
Endocrinology; 1994 Feb; 134(2):521-8. PubMed ID: 8299552
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-1 receptor antagonist inhibits growth modulation of human tumor-cell lines by interleukin-1 in-vitro.
Oelmann E; Topp M; Reufi B; Papadimitriou C; Koenigsmann M; Oberberg D; Thiel E; Berdel W
Int J Oncol; 1994 Mar; 4(3):555-8. PubMed ID: 21566958
[TBL] [Abstract][Full Text] [Related]
17. Exogenous IL-1Ra attenuates intestinal mucositis induced by oxaliplatin and 5-fluorouracil through suppression of p53-dependent apoptosis.
Wang X; Gao J; Qian L; Gao J; Zhu S; Wu M; Zhang Y; Guan W; Ye H; Yu Y; Han W
Anticancer Drugs; 2015 Jan; 26(1):35-45. PubMed ID: 24999837
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor activity of cisplatin and interleukin 1 in sensitive and resistant solid tumors.
Braunschweiger PG; Basrur VS; Santos O; Markoe AM; Houdek PV; Schwade JG
Cancer Res; 1993 Mar; 53(5):1091-7. PubMed ID: 8439953
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.
Cameron RB; McIntosh JK; Rosenberg SA
Cancer Res; 1988 Oct; 48(20):5810-7. PubMed ID: 3262413
[TBL] [Abstract][Full Text] [Related]
20. The role of interleukin 1 in growth and metastasis of human cancer xenografts.
Elaraj DM; Weinreich DM; Varghese S; Puhlmann M; Hewitt SM; Carroll NM; Feldman ED; Turner EM; Alexander HR
Clin Cancer Res; 2006 Feb; 12(4):1088-96. PubMed ID: 16489061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
